Luxeptinib - CAS 1616428-23-9

Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].

BTK, Others, Apoptosis, FLT

Tyrosine Kinase/Adaptors, Apoptosis, Others, Angiogenesis

1616396

C25H17F4N5O2

495.43

Cc1c[nH]c(n1)-c1ccc(c2CNC(=O)c12)-c1ccc(NC(=O)Nc2c(F)cc(F)cc2F)cc1F

-20°C

Ice Packs

Small Compound